Nicox: Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development UpdateMore patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprostNew analysis provides additional data demonstrating differentiation of NCX 470Development activities on track for U.S. New Drug Application submission targeted in H1 2026March 3, 2025 - release at 7:30 am CETSophia Antipolis, FranceNicox SA (PARIS:FR, ALCOX)), an international ophthalmology company, today provided details of a poster presentation highlighting additional pre-planned analysis from the NCX 470 Mont Blanc Phase 3 clinical trial at the 2025 American Glaucoma Society (AGS) Annual Meeting, one of the key scientific events in vision research, which was held on February 26 to March 2, 2025 in Washington, United States. The Company also provided an update on NCX 470 Development. "These data provide another example of where NCX 470 is differentiated from the standard-of-care for intraocular pressure reduction, latanoprost. In this analysis, we demonstrated that more patients achieve intraocular pressure of less than or equal to 18 mmHg on NCX 470 than on latanoprost. In addition, the mean percentage reduction in intraocular pressure was greater in patients on NCX 470 compared to those on latanoprost." said Doug Hubatsch, Chief Scientific Officer of Nicox. "We also look forward to announcing the results of the Whistler trial, investigating the mechanism of action of NCX 470, shortly, and the second pivotal Phase 3 trial, Denali, in Q3 of this year." Poster Title: Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC TrialA statistically significant greater proportion of eyes treated with NCX 470 0.1% achieved mean diurnal IOPs of ≤18 mmHg compared to those in the latanoprost 0.005% group in this analysis of the multinational Phase 3 Mont Blanc clinical trial. Additionally, greater mean percent IOP reductions from baseline were seen in the eyes treated with NCX 470 than in eyes treated with latanoprost.Summary of key differentiating factors seen in post hoc analysis of Mont BlancStatistically significant percentage of patients achieve ≤ 18mmHg IOP on NCX 470 ...Full story available on Benzinga.com